Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing.
PURPOSE: This phase I trial is studying the best dose of mibefradil dihydrochloride when
given together with temozolomide in treating patients with glioma.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Cavion LLC Jazz Pharmaceuticals National Cancer Institute (NCI)